Non-small cell lung cancers (NSCLCs) with acquired epidermal growth factor receptor (EGFR) mutations that are resistant to EGFR tyrosine kinase inhibitors (TKIs) represent a neglected and difficult-to-treat subtype of lung cancers [1–4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.